 |
|
|
| |
Lead-in Cohort Results From a Phase 2 Study of a Novel 8-week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients With Chronic Hepatitis C Virus Infection
|
| |
| |
European Association for the Study of the Liver (EASL) 2024 Congress, 5-8 June, Milan, Italy.
Alina Jucov,1 Brian Conway,2 Laura Iliescu,3 Paul Mitrut,4 Simin Florescu,5 Roxana Cernat,6 Elena Ermacicova,7 Shannan Lynch,8 Marina Majarian,8 Sergey Izmailyan,8 Xiao-Jian Zhou,8 Keith Pietropaolo,8 Bruce Belanger,8
Arantxa Horga,8 Qi Huang,8 and Janet Hammond8
1Arensia Exploratory Medicine GmbH and Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova; 2Vancouver Infectious Diseases Centre, Vancouver, Canada; 3Institutul Clinic Fundeni, Bucharest, Romania; 4University of Medicine and Pharmacy, Craiova, Romania; 5Spitalul Clinic Dr. Victor Babes, Bucharest, Romania; 6Clinical Hospital for Infectious Diseases, "Ovidius" University, Constanta, Romania; 7Arensia Exploratory Medicine GmbH, Chisinau, Moldova; 8Atea Pharmaceuticals, Inc., Boston, USA
|
| |
|
|
|
|
|
